HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

WanYing Lin Selected Research

Neoplasms (Cancer)

11/2020Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


WanYing Lin Research Topics

Disease

2Weaver syndrome
11/2023 - 06/2023
2Prostatic Neoplasms (Prostate Cancer)
11/2020 - 01/2018
1Neoplasms (Cancer)
11/2020
1Neoplasm Metastasis (Metastasis)
01/2018
1Kidney Neoplasms (Kidney Cancer)
01/2017
1Renal Cell Carcinoma (Grawitz Tumor)
01/2017
1Urinary Bladder Neoplasms (Bladder Cancer)
12/2015

Drug/Important Bio-Agent (IBA)

4Androgen Receptors (Androgen Receptor)IBA
11/2020 - 12/2015
2MethyltransferasesIBA
11/2023 - 06/2023
2Polycomb Repressive Complex 2IBA
11/2023 - 06/2023
2enzalutamideIBA
11/2020 - 01/2018
2AndrogensIBA
11/2020 - 01/2018
1Cisplatin (Platino)FDA LinkGeneric
11/2020
1Carboplatin (JM8)FDA LinkGeneric
11/2020
1bicalutamide (Casodex)FDA LinkGeneric
01/2018
1abirateroneIBA
01/2018
1Androgen Antagonists (Antiandrogens)IBA
01/2018
1hydrogen sulfite (bisulfite)IBA
01/2017
1MicroRNAs (MicroRNA)IBA
01/2017
1Long Noncoding RNAIBA
01/2017

Therapy/Procedure

2Castration
11/2020 - 01/2018
2Therapeutics
11/2020 - 01/2018
1Drug Therapy (Chemotherapy)
11/2020
1Radiotherapy
11/2020